PARD (Poniard Pharmaceuticals) Net Income: $-16.04 Mil (TTM As of Sep. 2011)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Poniard Pharmaceuticals Net Income?

Poniard Pharmaceuticals PARD Net Income is $-16.04 Mil as of Sep. 2011.

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Poniard Pharmaceuticals's Net Income for the three months ended in Sep. 2011 was $-3.77 Mil. Its Net Income for the trailing twelve months (TTM) ended in Sep. 2011 was $-16.04 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Poniard Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Sep. 2011 was $-2.55.

Poniard Pharmaceuticals  (OTCPK:PARD) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Poniard Pharmaceuticals's Earnings per Share (Diluted) (EPS) for the quarter that ended in Sep. 2011 is calculated as

Earnings per Share (Diluted) (Q: Sep. 2011 )=(Net Income-Preferred Dividends)/Shares Outstanding (Diluted Average)
=(-3.771-0.048)/1.498
=-2.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.

Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.

Poniard Pharmaceuticals Net Income Related Terms

Poniard Pharmaceuticals Net Income Historical Data

* Premium members only.

The historical data trend for Poniard Pharmaceuticals's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals Net Income Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -23.29 -32.78 -48.57 -45.72 -30.05

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.45 -5.17 -3.25 -3.86 -3.77

Poniard Pharmaceuticals Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Poniard Pharmaceuticals's Net Income for the fiscal year that ended in Dec. 2010 is calculated as

Net Income(A: Dec. 2010 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=0+0+0+-30.051
=-30.05

Poniard Pharmaceuticals's Net Income for the quarter that ended in Sep. 2011 is calculated as

Net Income(Q: Sep. 2011 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=0+0+0+-3.771
=-3.77

Net Income for the trailing twelve months (TTM) ended in Sep. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Income →
What does a Net Income of $-16.04 Mil mean?
Poniard Pharmaceuticals (PARD) has a Net Income of $-16.04 Mil as of Sep. 2011. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on Poniard Pharmaceuticals and its competitors.
Is Poniard Pharmaceuticals' Net Income too high?
Poniard Pharmaceuticals' current Net Income is $-16.04 Mil.
How does Poniard Pharmaceuticals' Net Income compare to OBMP and NSPX?
Poniard Pharmaceuticals' Net Income of $-16.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income for a Biotechnology company?
A good Net Income depends on the Biotechnology industry context. However, Net Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income mean?
A high Net Income can signal that a stock is expensive relative to its fundamentals. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on Poniard Pharmaceuticals and its competitors. Poniard Pharmaceuticals's current Net Income is $-16.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poniard Pharmaceuticals stock overvalued right now?
Poniard Pharmaceuticals (PARD) has a current Net Income of $-16.04 Mil. The current Net Income is $-16.04 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income calculated?
Net Income is calculated from a company's financial statements. For Poniard Pharmaceuticals (PARD), the current Net Income is $-16.04 Mil as of Sep. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.